Ghent University Hospital | General and Hepatobiliary Surgery

Research site

(Unclaimed)

Location

Corneel Heymanslaan 10, Gent, East Flanders, Belgium

Site insights

Top conditions

Top treatments

Lenalidomide

Bevacizumab

PLN-74809

Tal-DR

Nintedanib

Ustekinumab

Psilocybin

Secukinumab

Ribavirin

Elotuzumab

Parent organization

This site is a part of Ghent University Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 46 total trials

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting

Marginal Zone Lymphoma

Follicular Lymphoma

Drug: tafasitamab

Drug: placebo

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) w...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Elotuzumab

Drug: Bortezomib

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting

Colitis, Ulcerative

Drug: Placebo

Drug: JNJ-77242113

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Talquetamab

Effectiveness of 3M Cavilon Advanced Skin Protectant in the Treatment of Moisture-associated Skin Damage in Hospitals (ISR-CASP-MASD)

Objectives: The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the treatment of partial-thickness wou...

Not yet enrolling

Wound of Skin

Stoma Site Dermatitis

Device: 3M Cavilon Advanced Skin Protectant

Device: Standard hospital wound treatment protocol

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

Active, not recruiting

X-Linked Retinitis Pigmentosa

Biological: Genetic: AAV5-hRKp.RPGR Intermediate Dose

Biological: Genetic: AAV5-hRKp.RPGR Low Dose

Psilocybin for Hospitalized Patients with Treatment-resistant Depression (PSIHOS-D)

The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for tre...

Enrolling

Treatment Resistant Depression

Drug: Psilocybin

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204)

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...

Active, not recruiting

Endometrial Cancer

Drug: INCAGN02385

Drug: pemigatinib

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are R...

Enrolling

Myelodysplastic Syndromes

Drug: Placebo

Drug: Tamibarotene